STAT3 and Miyoshi myopathy: siRNAs remain largely preclinical, with efforts like STAT3 or MYC siRNA via nanoparticle delivery showing promise in reducing MM proliferation and sensitizing cells to bortezomib [203], though, other than Dicerna’s anti-MYC siRNA ‘DCR-MYC’, no MM-specific clinical trials have emerged yet.